NCT05364554 (FRONTIER 2) is a Phase 2 clinical trial of JNJ-77242113 in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT05364554?

NCT05364554 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT05364554?

Interventions in NCT05364554: JNJ-77242113.

What condition does NCT05364554 study?

NCT05364554 studies Plaque Psoriasis.

Is NCT05364554 still recruiting?

NCT05364554 is currently completed. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT05364554: FRONTIER 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

Completed Phase 2 Last updated 12 September 2025

What this trial tests

Phase 2 trial testing JNJ-77242113 in Plaque Psoriasis in 227 participants. Completed in 29 September 2023.

Timeline

10 June 2022

Primary endpoint
29 September 2023

29 September 2023

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	227
Start date	10 June 2022
Primary completion	29 September 2023
Estimated completion	29 September 2023
Sites	60 locations across France, Japan, Taiwan, United Kingdom, Germany, Poland, South Korea, Canada

Drugs / interventions tested

JNJ-77242113 — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.
Carmona-Rocha E, Rusiñol L, Puig L. · · 2024 · cited 28× · PMID 38399292 · DOI 10.3390/pharmaceutics16020239
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.
Drakos A, Torres T, Vender R. · · 2024 · cited 21× · PMID 38258121 · DOI 10.3390/pharmaceutics16010111
A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.
Drakos A, Vender R. · · 2022 · cited 15× · PMID 36319883 · DOI 10.1007/s13555-022-00840-9
Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.
Knight B, Tammara B, Modi NB, Dallas S, et al · · 2025 · cited 7× · PMID 40629250 · DOI 10.1007/s13555-025-01454-7
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.
Stein Gold L, Eyerich K, Merola JF, Torres J, et al · · 2025 · cited 7× · PMID 40439953 · DOI 10.1007/s12325-025-03213-8
Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas.
LaRoche JK, Lanier J, Alvarenga R, Collins M, et al · · 2025 · cited 4× · PMID 39971605 · DOI 10.1136/bmjopen-2024-085364
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
Strawn D, Krueger JG, Bissonnette R, Eyerich K, et al · · 2025 · cited 2× · PMID 41424381 · DOI 10.1172/jci.insight.193563

Verify or expand the search:

Other trials of JNJ-77242113

Trials testing the same drug.

NCT06934226 — A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate · Phase 3 · active not recruiting
NCT06220604 — A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) · Phase 3 · active not recruiting
NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT06143878 — A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis · Phase 3 · active not recruiting
NCT06095102 — A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, · Phase 3 · active not recruiting

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05364554 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05364554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing